Online inquiry

IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6092MR)

This product GTTS-WQ6092MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6092MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12977MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ2525MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ5463MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ1077MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ2283MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ8280MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ11645MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ15933MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW